59 reports of this reaction
1.9% of all HALOBETASOL PROPIONATE reports
#9 most reported adverse reaction
DERMATITIS ATOPIC is the #9 most commonly reported adverse reaction for HALOBETASOL PROPIONATE, manufactured by Lacer Pharma, LLC. There are 59 FDA adverse event reports linking HALOBETASOL PROPIONATE to DERMATITIS ATOPIC. This represents approximately 1.9% of all 3,036 adverse event reports for this drug.
Patients taking HALOBETASOL PROPIONATE who experience dermatitis atopic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DERMATITIS ATOPIC is a less commonly reported adverse event for HALOBETASOL PROPIONATE, but still significant enough to appear in the safety profile.
In addition to dermatitis atopic, the following adverse reactions have been reported for HALOBETASOL PROPIONATE:
The following drugs have also been linked to dermatitis atopic in FDA adverse event reports:
DERMATITIS ATOPIC has been reported as an adverse event in 59 FDA reports for HALOBETASOL PROPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DERMATITIS ATOPIC accounts for approximately 1.9% of all adverse event reports for HALOBETASOL PROPIONATE, making it a notable side effect.
If you experience dermatitis atopic while taking HALOBETASOL PROPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.